Inandex (Dexamethasone Phosphate)

Dexamethasone phosphate binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus. This complex regulates gene transcription, increasing anti‑inflammatory proteins and decreasing pro‑inflammatory cytokines, thereby reducing swelling, pain and immune‑mediated tissue damage.

The dose of Inandex is individualized by the prescribing clinician based on the specific indication, severity of disease, patient weight, renal function and route of administration. Healthcare professionals determine the appropriate amount and schedule for each patient.

Safety data for dexamethasone phosphate in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Inandex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Inandex delivers dexamethasone phosphate, a potent, long‑acting glucocorticoid with high anti‑inflammatory potency. Compared with shorter‑acting steroids such as hydrocortisone, dexamethasone provides stronger suppression of inflammation with less frequent dosing, but it also carries a higher risk of systemic side effects if used long‑term.

Inandex should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain its stability and sterility.

Inandex is supplied as a sterile injectable solution and can be given by infiltration, intramuscular injection or intravenous infusion, depending on the clinical situation. Administration is performed by qualified healthcare personnel following aseptic technique and appropriate dosing guidelines.

Serious risks include adrenal suppression or crisis on abrupt discontinuation, severe infections due to immunosuppression, gastrointestinal bleeding, psychiatric disturbances such as psychosis, and rare anaphylactic reactions. Patients should be monitored closely for these events, especially during high‑dose or prolonged therapy.

Inandex is contraindicated in patients with known hypersensitivity to dexamethasone or any excipients, those with systemic fungal infections, and individuals receiving live vaccines. Caution is also advised for patients with uncontrolled diabetes, severe hypertension, or active peptic ulcer disease.